These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 31808966)

  • 1. Glycogen synthase kinase 3β as a potential therapeutic target in synovial sarcoma and fibrosarcoma.
    Abe K; Yamamoto N; Domoto T; Bolidong D; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Inatani H; Aoki Y; Higuchi T; Taniguchi Y; Yonezawa H; Araki Y; Aiba H; Minamoto T; Tsuchiya H
    Cancer Sci; 2020 Feb; 111(2):429-440. PubMed ID: 31808966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential therapeutic effect of targeting glycogen synthase kinase 3β in esophageal squamous cell carcinoma.
    Bolidong D; Domoto T; Uehara M; Sabit H; Okumura T; Endo Y; Nakada M; Ninomiya I; Miyashita T; Wong RW; Minamoto T
    Sci Rep; 2020 Jul; 10(1):11807. PubMed ID: 32678196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma.
    Miyashita K; Kawakami K; Nakada M; Mai W; Shakoori A; Fujisawa H; Hayashi Y; Hamada J; Minamoto T
    Clin Cancer Res; 2009 Feb; 15(3):887-97. PubMed ID: 19188159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity.
    Dong J; Peng J; Zhang H; Mondesire WH; Jian W; Mills GB; Hung MC; Meric-Bernstam F
    Cancer Res; 2005 Mar; 65(5):1961-72. PubMed ID: 15753396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of glycogen synthase kinase 3β overexpression in rat and glycogen synthase kinase 3β inhibitor SB-216763 on proliferation of hepatic oval cells].
    Zhong JQ; Xie YK; Ji XK; Fu JH; Wang Y; Zhang QY; Shi HQ; Shan YF
    Zhonghua Wai Ke Za Zhi; 2012 Nov; 50(11):1003-6. PubMed ID: 23302485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells.
    Kunnimalaiyaan M; Vaccaro AM; Ndiaye MA; Chen H
    Mol Cancer Ther; 2007 Mar; 6(3):1151-8. PubMed ID: 17363508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients.
    Vlenterie M; Hillebrandt-Roeffen MH; Schaars EW; Flucke UE; Fleuren ED; Navis AC; Leenders WP; Versleijen-Jonkers YM; van der Graaf WT
    Ann Surg Oncol; 2016 Sep; 23(9):2745-52. PubMed ID: 27334220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin induces G
    Chen MJ; Cheng AC; Lee MF; Hsu YC
    J Cell Physiol; 2018 Jun; 233(6):4618-4625. PubMed ID: 28833099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GSK3β-dependent cyclin D1 and cyclin E1 degradation is indispensable for NVP-BEZ235 induced G0/G1 arrest in neuroblastoma cells.
    Liu SL; Liu Z; Zhang LD; Zhu HQ; Guo JH; Zhao M; Wu YL; Liu F; Gao FH
    Cell Cycle; 2017; 16(24):2386-2395. PubMed ID: 28980866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the GSK-3β inhibitor (2Z,3E)-6-bromoindirubin-3'-oxime upon ovarian cancer cells.
    Yu AS; Zhao L
    Tumour Biol; 2016 Apr; 37(4):4857-64. PubMed ID: 26526575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of glycogen synthase kinase-3β targeting against osteosarcoma via activation of β-catenin.
    Shimozaki S; Yamamoto N; Domoto T; Nishida H; Hayashi K; Kimura H; Takeuchi A; Miwa S; Igarashi K; Kato T; Aoki Y; Higuchi T; Hirose M; Hoffman RM; Minamoto T; Tsuchiya H
    Oncotarget; 2016 Nov; 7(47):77038-77051. PubMed ID: 27780915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphatidylinositol-3'-kinase/AKT signaling is essential in synovial sarcoma.
    Friedrichs N; Trautmann M; Endl E; Sievers E; Kindler D; Wurst P; Czerwitzki J; Steiner S; Renner M; Penzel R; Koch A; Larsson O; Tanaka S; Kawai A; Schirmacher P; Mechtersheimer G; Wardelmann E; Buettner R; Hartmann W
    Int J Cancer; 2011 Oct; 129(7):1564-75. PubMed ID: 21128248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SRC signaling is crucial in the growth of synovial sarcoma cells.
    Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
    Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
    Ishibe T; Nakayama T; Okamoto T; Aoyama T; Nishijo K; Shibata KR; Shima Y; Nagayama S; Katagiri T; Nakamura Y; Nakamura T; Toguchida J
    Clin Cancer Res; 2005 Apr; 11(7):2702-12. PubMed ID: 15814652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine.
    Shimasaki T; Ishigaki Y; Nakamura Y; Takata T; Nakaya N; Nakajima H; Sato I; Zhao X; Kitano A; Kawakami K; Tanaka T; Takegami T; Tomosugi N; Minamoto T; Motoo Y
    J Gastroenterol; 2012 Mar; 47(3):321-33. PubMed ID: 22041920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wogonin inhibits cell cycle progression by activating the glycogen synthase kinase-3 beta in hepatocellular carcinoma.
    Hong M; Almutairi MM; Li S; Li J
    Phytomedicine; 2020 Mar; 68():153174. PubMed ID: 31991293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Thujaplicin inhibits basal-like mammary tumor growth by regulating glycogen synthase kinase-3β/β-catenin signaling.
    Chen J; Ko J; Kim JT; Cho JS; Qiu S; Kim GD; Auh JH; Lee HJ
    Food Funct; 2019 May; 10(5):2691-2700. PubMed ID: 31026007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumol induces cell cycle arrest in colon cancer cells via reactive oxygen species and Akt/ GSK3β/cyclin D1 pathway.
    Wang J; Li XM; Bai Z; Chi BX; Wei Y; Chen X
    J Ethnopharmacol; 2018 Jan; 210():1-9. PubMed ID: 28684297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant nuclear accumulation of glycogen synthase kinase-3beta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation.
    Ougolkov AV; Fernandez-Zapico ME; Bilim VN; Smyrk TC; Chari ST; Billadeau DD
    Clin Cancer Res; 2006 Sep; 12(17):5074-81. PubMed ID: 16951223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma.
    Ugolkov AV; Bondarenko GI; Dubrovskyi O; Berbegall AP; Navarro S; Noguera R; O'Halloran TV; Hendrix MJ; Giles FJ; Mazar AP
    Anticancer Drugs; 2018 Sep; 29(8):717-724. PubMed ID: 29846250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.